Grove Biopharma
PrivateLast Round
Series A
Apr 23, 2025
Total Funding Raised
$34.25M
Momentum Score
100 /100
Company Overview
Grove Biopharma is a private, venture-backed biotechnology company that spun out of Northwestern University. Based in Chicago, the company is pioneering a new therapeutic modality known as Bionic Biologics™, a platform that integrates principles of biologic and synthetic design to create cell-penetrating drugs. This technology aims to address previously intractable intracellular protein-protein interactions, which are the cause of many diseases. The company's initial focus is on developing treatments for oncology and neurodegenerative diseases, with its lead program targeting an androgen receptor for castrate-resistant prostate cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Advanced Materials, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Grove Biopharma Comps
Public and private peers based on sector, stage, and business model.
Grove Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 23, 2025 | ||||
| Grant | Jul 15, 2023 | ||||
| Seed | May 10, 2021 |
Key People
Founding team and executive leadership
Grove Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Department of Health and Human Services | Grant |
| DCVC Bio | Series A |
| InVivium Capital | Series A |
| Mansueto Office | Series A |
| Walder Ventures | Seed, Series A |
| Skydeck Capital | Seed |
| Portal Innovations | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 15, 2025
Will participate in the Materials Biology symposium at the ACS Fall 2025 Scientific meeting.
- Apr 25, 2025
Developing therapeutic protein-like polymers as part of company launch.
Grove Biopharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Grove Biopharma's valuation, stock price, and market status.
